Internal Medicine, Cardiovascular Disease · Amarillo, TX
NPI
1447424007
Since 2008
Specialty
Internal Medicine, Cardiovascular Disease
Code 207RC0000X
Group practices
3
Medicare group memberships
Hospitals
5
Hospital affiliations
6200 I-40 W
Amarillo, TX, 79106
Phone (806) 354-9764
Groups this clinician bills Medicare through
Medicare paid, 2024
$856K
15,630 services
Medicare patients, 2024
1,926
Average age 75
Drug cost, 2024
$2.4M
12,610 prescriptions
Company payments, 2025
$16K
From 16 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by David G Brabham was code J1306 (injection, inclisiran, 1 mg), 5,964 times for 13 patients. In total David G Brabham billed 15,630 services in 83 codes, and Medicare paid $856K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2011-05-03.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J1306 Injection, inclisiran, 1 mg | Office | 5,964 | 13 | $9.40 | $56K |
| 99490 Chronic, Principal, and Transitional Care Management | Office | 2,514 | 282 | $46.68 | $117K |
| 99214 Office E&M - Established | Office | 953 | 723 | $91.49 | $87K |
| 99426 Chronic, Principal, and Transitional Care Management | Office | 833 | 97 | $47.18 | $39K |
| 99457 E&M - Miscellaneous | Office | 692 | 92 | $37.43 | $26K |
| 93010 Electrocardiogram | Facility | 607 | 443 | $6.07 | $3,684 |
| 99454 E&M - Miscellaneous | Office | 597 | 88 | $35.34 | $21K |
| J2785 Injection, regadenoson, 0.1 mg | Office | 496 | 123 | $5.14 | $2,551 |
| 78434 Myocardial Perfusion Scan | Office | 325 | 324 | $146.91 | $48K |
| 78431 Myocardial Perfusion Scan | Office | 325 | 324 | $616.31 | $200K |
| 93356 Echocardiography (TTE/TEE) | Office | 255 | 239 | $29.12 | $7,427 |
| 93306 Echocardiography (TTE/TEE) | Office | 231 | 227 | $148.67 | $34K |
| 85610 Clinical Chemistry | Office | 211 | 28 | $4.18 | $883 |
| 93000 Electrocardiogram | Office | 191 | 185 | $10.43 | $1,991 |
| 99204 Office E&M - New | Office | 152 | 152 | $109.02 | $17K |
By year: 2022 $693K for 9,342 services; 2023 $814K for 12,691 services; 2024 $856K for 15,630 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 85610 Clinical Chemistry | 211 | 28 | $4.18 | $883 |
Medicare prescription drug claims, 2024
In 2024, the drug David G Brabham prescribed most often to Medicare patients was Carvedilol, with 1,504 prescriptions and refills. In total David G Brabham wrote 12,610 Medicare prescriptions that cost $2.4M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Carvedilol Generic | 1,504 | 3,374 | 392 | $11K |
| Spironolactone Generic | 1,204 | 2,417 | 314 | $10K |
| Atorvastatin Calcium Generic | 828 | 2,065 | 231 | $6,953 |
| Eliquis Apixaban | 802 | 1,408 | 197 | $807K |
| Clopidogrel Clopidogrel Bisulfate | 786 | 1,691 | 207 | $7,076 |
| Furosemide Generic | 719 | 1,511 | 255 | $3,174 |
| Entresto Sacubitril/Valsartan | 669 | 992 | 164 | $645K |
| Rosuvastatin Calcium Generic | 611 | 1,340 | 175 | $7,546 |
| Jardiance Empagliflozin | 490 | 731 | 104 | $408K |
| Lisinopril Generic | 457 | 1,107 | 123 | $3,273 |
| Losartan Potassium Generic | 317 | 745 | 82 | $3,491 |
| Isosorbide Mononitrate Er Isosorbide Mononitrate | 305 | 648 | 82 | $3,512 |
| Metoprolol Tartrate Generic | 297 | 707 | 84 | $1,751 |
| Metoprolol Succinate Generic | 284 | 691 | 95 | $4,522 |
| Amlodipine Besylate Generic | 283 | 623 | 85 | $1,746 |
Brand drugs: 2,519 claims; generic drugs: 10,091 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid David G Brabham $16K ($16K in general payments such as food, travel and fees) from 16 companies. The largest payer was Boehringer Ingelheim Pharmaceuticals, Inc. with $6,740.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.